Agennix AG / Agennix AG to Present at Close Brothers Seydler Small and Mid Cap Conference in Frankfurt on February 4  processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. 

Company also Announces Fiscal Year 2009 Reporting Date will be March 24, 2010

Martinsried/Munich  (Germany), Princeton, NJ and Houston, TX, February 2, 2010 -
Agennix AG (Frankfurt Stock Exchange: AGX) today announced that the Company will
give  a corporate  presentation at  the upcoming  Close Brothers Seydler Bank AG
Small  and Mid  Cap Conference.  The presentation  will be on Thursday, February
4, 2010 at the IHK Frankfurt (Boerse), Frankfurt am Main, Germany.

The  Company also announced that it will  report its business results for fiscal
year  2009 on Wednesday, March 24, 2010. Agennix will  hold a conference call to
discuss  the results and provide a corporate update on that day. Details will be
published in advance of the call.

About Agennix
Agennix  AG is  a publicly  traded biopharmaceutical  company that is developing
novel  therapies in areas of major unmet  medical need to improve the length and
quality  of life of seriously ill patients.  The Company's most advanced program
is talactoferrin, an oral targeted therapy that is in Phase 3 clinical trials in
non-small  cell lung cancer. Agennix also has recently reported positive results
from  a Phase 2 trial evaluating talactoferrin in severe sepsis.  Other clinical
development  programs include  RGB-286638, a  multi-targeted kinase inhibitor in
Phase 1 testing; the oral platinum-based compound satraplatin; and a topical gel
form  of  talactoferrin  for  diabetic  foot  ulcers. Agennix is a transatlantic
company with sites in Munich, Germany; Princeton, New Jersey and Houston, Texas.
For   additional   information,   please   visit   the   Agennix   Web  site  at
www.agennix.com.

This  press  release  contains  forward-looking  statements,  which  express the
current  beliefs  and  expectations  of  the  management  of  Agennix  AG.  Such
statements  are  based  on  current  expectations  and  are subject to risks and
uncertainties,  many of  which are  beyond our  control, that could cause future
results,  performance or achievements to  differ significantly from the results,
performance  or  achievements  expressed  or  implied  by  such  forward-looking
statements.  Actual results  could differ  materially depending  on a  number of
factors,   and  we  caution  investors  not  to  place  undue  reliance  on  the
forward-looking  statements  contained  in  this  press release. Forward-looking
statements  speak  only  as  of  the  date  on  which  they are made and Agennix
undertakes no obligation to update these forward-looking statements, even if new
information becomes available in the future.


For further information, please contact:

Agennix
AG
Investor Relations & Corporate Communications
Phone: +49 (0)89 8565 2693
ir@agennix.com


In the U.S.: Laurie Doyle
Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884
laurie.doyle@agennix.com 

Additional media contacts for Europe:
MC Services AG
Phone: +49 (0) 89 210 228 0

Raimund Gabriel
raimund.gabriel@mc-services.eu


Hilda Juhasz
hilda.juhasz@mc-services.eu 

Additional investor contact for Europe:
Trout International LLC
Lauren Williams, Vice President
Phone: +44 207 936 9325
lwilliams@troutgroup.com 




[HUG#1379491]



 --- End of Message --- 

Agennix AG
Fraunhoferstr. 20 Martinsried Germany

ISIN: DE000A1A6XX4;
Listed: Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;